JP2023554097A5 - - Google Patents
Info
- Publication number
- JP2023554097A5 JP2023554097A5 JP2023537140A JP2023537140A JP2023554097A5 JP 2023554097 A5 JP2023554097 A5 JP 2023554097A5 JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023554097 A5 JP2023554097 A5 JP 2023554097A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bifunctional molecule
- molecule according
- antigen
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2020/086600 WO2021122866A1 (en) | 2019-12-17 | 2020-12-17 | Bifunctional molecules comprising an il-7 variant |
| EPPCT/EP2020/086600 | 2020-12-17 | ||
| EP21305462.0 | 2021-04-09 | ||
| EP21305462 | 2021-04-09 | ||
| EP21200350 | 2021-09-30 | ||
| EP21200350.3 | 2021-09-30 | ||
| PCT/EP2021/086471 WO2022129512A1 (en) | 2020-12-17 | 2021-12-17 | Bifunctional anti-pd1/il-7 molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554097A JP2023554097A (ja) | 2023-12-26 |
| JP2023554097A5 true JP2023554097A5 (enExample) | 2024-12-25 |
Family
ID=79024880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537140A Pending JP2023554097A (ja) | 2020-12-17 | 2021-12-17 | 二機能性抗ｐｄ１／ｉｌ－７分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240067727A1 (enExample) |
| EP (1) | EP4263606A1 (enExample) |
| JP (1) | JP2023554097A (enExample) |
| KR (1) | KR20230129441A (enExample) |
| AU (1) | AU2021402065A1 (enExample) |
| CA (1) | CA3201729A1 (enExample) |
| IL (1) | IL303745A (enExample) |
| MX (1) | MX2023007301A (enExample) |
| WO (1) | WO2022129512A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4366781A1 (en) * | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| US20240424127A1 (en) * | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| CN118359730A (zh) * | 2023-01-17 | 2024-07-19 | 上海君赛生物科技有限公司 | 包含细胞因子的靶向型融合蛋白 |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| ES2305886T3 (es) * | 2003-12-30 | 2008-11-01 | Merck Patent Gmbh | Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo. |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| AU2007271398B2 (en) * | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| JP6594855B2 (ja) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| MY192158A (en) | 2016-09-14 | 2022-08-03 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies and their uses |
| BR112020010536A2 (pt) | 2018-01-25 | 2020-12-01 | I-Mab Biopharma Us Limited | molécula de fusão, proteína e célula isoladas, composição, e, método para tratar um câncer |
| EP3781598A1 (en) * | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| SG11202010163QA (en) * | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CN112566801B (zh) | 2018-07-10 | 2024-03-01 | 依维柯股份公司 | 用于车辆的悬架 |
| ES2963700T3 (es) | 2018-12-21 | 2024-04-01 | Ose Immunotherapeutics | Anticuerpo humanizado anti-PD-1 humana |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
| WO2021122866A1 (en) * | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
-
2021
- 2021-12-17 US US18/267,795 patent/US20240067727A1/en active Pending
- 2021-12-17 WO PCT/EP2021/086471 patent/WO2022129512A1/en not_active Ceased
- 2021-12-17 CA CA3201729A patent/CA3201729A1/en active Pending
- 2021-12-17 EP EP21831061.3A patent/EP4263606A1/en active Pending
- 2021-12-17 IL IL303745A patent/IL303745A/en unknown
- 2021-12-17 JP JP2023537140A patent/JP2023554097A/ja active Pending
- 2021-12-17 AU AU2021402065A patent/AU2021402065A1/en active Pending
- 2021-12-17 KR KR1020237023523A patent/KR20230129441A/ko active Pending
- 2021-12-17 MX MX2023007301A patent/MX2023007301A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554097A5 (enExample) | ||
| JP2019533441A5 (enExample) | ||
| IL269395B1 (en) | Immunoconjugations of anti–PD–1 antibody with IL–2 or IL–15 mutation | |
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| JP2019530434A5 (enExample) | ||
| JP2018516537A5 (enExample) | ||
| JP2024119791A5 (enExample) | ||
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| JP2019500891A5 (enExample) | ||
| JP2019500892A5 (enExample) | ||
| US20210198368A1 (en) | Multispecific molecules targeting cll-1 | |
| JP2021521275A5 (enExample) | ||
| WO2020023702A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| JP2022512649A5 (enExample) | ||
| JP2021525082A5 (enExample) | ||
| RU2016133347A (ru) | Варианты fc-области с улучшенной способностью связываться с белком а | |
| RU2018143439A (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент | |
| JP2019500893A5 (enExample) | ||
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2020502233A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2018525382A5 (enExample) | ||
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| JP2018520650A5 (enExample) | ||
| JP2012530496A5 (enExample) |